The Record Special Sections Health Quarterly 02-16-2020 | Page 16

16 ❚ SUNDAY, FEBRUARY 16, 2020 ❚ THE RECORD
HEALTH QUARTERLY / ADVERTISING SECTION
HACKENSACK UNIVERSITY MEDICAL CENTER
HUMC Launches Life-Saving
Kidney Transplant Technology
Hypothermic Machine Increases Kidney Viability, Lifespan
I
n January, Hackensack Meridian
Hackensack University Medical
Center became the first hospital in
the New Jersey to perform a kidney
transplant with a kidney preserved
at its own Organ
Preservation
Center using the
LifePort Kidney
Transporter, an ex
vivo hypothermic
machine preserva-
tion technology.
Hypothermic machine preservation
is a cutting-edge, life-saving technology
that increases a kidney’s viability and
lifespan, improving patient outcomes.
“Hackensack University Medical
Center is dedicated to providing the
safest, highest quality care for patients,”
said Mark D. Sparta, FACHE, president
and chief hospital executive, Hackensack
University Medical Center and execu-
tive vice president of Population Health,
Hackensack Meridian Health. “We are
so proud of our kidney transplant team,
who is leading the way in reducing wait
times and increasing survival rates.
This innovative technology will help us
improve patient outcomes.”
Michael J. Goldstein, M.D., FACS,
director of Organ Transplantation, dir-
ector of kidney & pancreas transplanta-
tion, Division of Organ Transplantation,
Hackensack University Medical Center,
performed the groundbreaking trans-
plant in January on Bronx, NY resident,
Arcadio Guzman, 38. Guzman is doing
well following the transplant.
“We are thrilled to become the first
hospital in New Jersey to offer this life-
saving kidney preservation technology
as part of routine transplant care to
expand the window of time in which a
kidney is viable and further reduce the
time it takes to receive a kidney trans-
plant,” said Dr. Goldstein. “This new
technology will help us improve patient
outcomes and save more lives.”
The Organ Transplantation Division
at Hackensack University Medical
Center recently marked a major mile-
stone in 2019 of performing 113 success-
ful transplants. Hackensack University
Medical Center’s renowned transplant
Hackensack
Is First Hospital
In U.S. to Implant
Congestive Heart
Failure Device
H
ackensack Meridian Hackensack University
Medical Center is the first hospital in the nation
to successfully implant the world’s first heart
failure neuromodulation device, BAROSTIM
NEO™. This innovative technology is an effective alter-
native for patients with Congestive Heart Failure (CHF)
who are ineligible for other forms of therapy such as
Cardiac Resynchronization Therapy (CRT).
“Hackensack University Medical Center is on the
forefront of delivering cutting-edge treatment for
our patients,” said Mark D. Sparta, FACHE, president
and chief hospital executive, Hackensack University
Medical Center and executive vice president of
Population Health,
Hackensack
Meridian Health.
“We are proud to be
the first hospital in
the nation to offer
this life-saving,
innovative device to
improve the quality
of life for heart fail-
ure patients.”
Patients with
Arcado Guzman is the first kidney transplant recipient to benefit from the life-
CHF suffer from
saving kidney preservation technology first introduced in New Jersey by Hackensack shortness of breath
University Medical Center.
and are limited to
CVRX
program has the second largest
mild daily activ-
BAROSTIM NEO™, the world’s
transplant program in New Jersey.
ity. Utilizing the
According to the Scientific Registry
nervous system to first heart failure neuromodula-
of Transplant Recipients, Hackensack
treat cardiovascu- tion device.
University Medical Center is ranked
lar disease, BAROSTIM NEO offers a groundbreaking
second in the nation among 263 trans-
treatment alternative for CHF patients. This state-
plant centers at providing life-saving
of-the-art device has the unique ability to improve
deceased donor kidneys faster and
heart performance, reduce hospital readmissions and
ranked third in the nation for the best
reduce the amount of medications patients take. It also
kidney survival at one year after trans-
increases mobility and reduces the risk of infection
plantation.
long-term for patients.
“This new, innovative technology is a promising
PHOTOS COURTESY OF HACKENSACK
alternative for patients suffering from heart failure,”
MERIDIAN HEALTH
said Massimo M. Napolitano, M.D., FACS, interim chair
Pictured with the LifePort Kidney
Department of Surgery, director of Vascular Services,
Transporter, which utilizes ex vivo
Hackensack University Medical Center. Dr. Napolitano
hypothermic preservation technology,
has traveled all over the United States teaching other
are Yuriy Yushkov, MD, PhD, MBA,
physicians how to implant BAROSTIM NEO. “Once the
manager, Organ Preservation Center,
device is implanted, complications from the implant
Hackensack University Medical
procedure are minimal and the patient’s mobility is
Center and Michael J. Goldstein,
greatly increased.”
M.D., FACS, director of Organ
BAROSTIM NEO uses CVRx-patented technology
Transplantation, director of kidney &
designed to trigger the body’s main cardiovascular reflex
pancreas transplantation, Division of
to treat patients suffering from chronic heart failure. It is
Organ Transplantation, Hackensack
designed to electrically activate the baroreflex, the body’s
University Medical Center.
natural mechanism to regulate cardiovascular function.